Communiqués WntResearch AB

Actions

WNT

SE0022239901

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
14 ^SEK	-2,44 %		+25,00 %	+52,17 %

20/06	WntResearch présente les observations ad hoc de l'étude NeoFox à l'ESMO GI	CI
03/05	WntResearch AB publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

WntResearch presents ad hoc observations from the NeoFox study at ESMO GI	20/06	AQ
WntResearch: WntResearch presents ad hoc observations from the NeoFox study at ESMO GI	20/06	PU
Redeye Initiates Coverage of WntResearch	13/06	AQ
WntResearch : Presentationen från AGM.	27/05	PU
WntResearch's CEO to BioStock: "If the effect is confirmed, there are good opportunities for licensing agreements next year"	08/05	AQ
BioStock: WntResearch's new CEO comments on his first month in the position	02/04	AQ
Resigning WntResearch CEO tells BioStock: "It will be exciting to follow!"	01/03	AQ
WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea	26/02	AQ
WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5	12/02	AQ
WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8	08/02	AQ
WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	07/02	AQ
WntResearch publishes outcome in rights issue	31/01	AQ
WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024	24/01	AQ
WntResearch publishes prospectus in connection with rights issue	08/01	AQ
Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023	22/12	AQ
WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5	06/12	AQ
WntResearch's CEO: "In a better position than ever"	21/11	AQ
BioStock: WntResearch recruits first patient in restart of NeoFox	20/10/23	AQ
BioStock: New patent strengthens WntResearch	06/10/23	AQ
BioStock Investor Meeting: WntResearch	27/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués WntResearch AB

Actions

WNT

SE0022239901

Communiqués

Filtres